In:
Cancer, Wiley, Vol. 129, No. 16 ( 2023-08-15), p. 2479-2490
Abstract:
Obesity is prevalent in adults with acute myeloid leukemia, and these patients are more likely to have intermediate‐risk cytogenetics and worse performance status; however, obesity does not affect clinical outcomes, including complete remission, early death, or overall survival. Dose modifications of daunorubicin (dose reductions and dose capping) in obese patients does not affect clinical outcomes; therefore, strict adherence to the full dose based on body surface area is not required for intensive therapy in adults with acute myeloid leukemia.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v129.16
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1